In September 2020, Valneva announced a collaboration with the UK Government, which has the option to purchase up to 190 million doses through 2025. The UK Government had ordered 60 million doses for supply in 2022. Valneva is a Whole Virus “Inactivated, Adjuvanted COVID-19 Vaccine” candidate. This technology is well-established and has been used in seasonal influenza, hepatitis A, polio and rabies vaccines.
In 2021 Valneva Commenced Submission to UK MHRA This was to receive Phase 3 Trials in UK prior to Licencing.
Fast forward to April 2022 and the Valneva vaccine has received a Condition Marketing Authoristion (CMA) by the MHRA for Great Britain and Northern Ireland – the first in the world to approve Valneva.
Now there are 6 vaccines currently in circulation. What makes Valneva particularly welcome is that it is a non mRNA based Covid vaccine and does need to be distributed source-to-patient at minus 70 degrees C !